Rossari Biotech Ltd
Rossari Biotech Ltd (ROSSARI) is scheduled to report results on 17 Oct 2026. Rossari Biotech Ltd last reported results for the quarter ended Jun 2026, with sales of ₹697 crore and net profit of ₹35 crore. The stock last traded at ₹434, a market capitalisation of ₹2,404 crore, on a P/E of 16.0. Over the past 52 weeks the stock has ranged between ₹373 and ₹691. Figures are as of 6 Oct 2026 and are not real time.
Rossari Biotech Ltd share price and key metrics
- Current price
- ₹434
- Market cap
- ₹2,404 cr
- Stock P/E
- 16.0
- Book value
- ₹241
- ROE
- 10.8%
- ROCE
- 13.3%
- Dividend yield
- 0.12%
- 52w high / low
- 691/373
Metrics as of 6 Oct 2026. Not real time.
Track Rossari Biotech Ltd
Cruxal reads every Rossari Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Rossari Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 28%
- 3 Years
- 13%
- TTM
- 19%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 8%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- -22%
- 3 Years
- -20%
- 1 Year
- -32%
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 12%
- Last Year
- 11%
Rossari Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹697 cr, up 28.1% from ₹544 cr a year earlier. Net profit was ₹35 cr, up 2.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 498 | 513 | 580 | 544 | 586 | 582 | 685 | 697 |
| Expenses | 432 | 448 | 510 | 476 | 514 | 513 | 608 | 617 |
| Operating profit | 66 | 65 | 69 | 68 | 72 | 69 | 77 | 81 |
| OPM % | 13% | 13% | 12% | 12% | 12% | 12% | 11% | 12% |
| Other income | 1 | 1 | 2 | 2 | 2 | 1 | 20 | 4 |
| Interest | 4 | 5 | 6 | 6 | 6 | 8 | 9 | 11 |
| Depreciation | 15 | 18 | 18 | 18 | 18 | 20 | 24 | 26 |
| Profit before tax | 48 | 42 | 48 | 46 | 50 | 43 | 64 | 48 |
| Tax % | 27% | 25% | 28% | 27% | 26% | 23% | 28% | 26% |
| Net profit | 35 | 32 | 34 | 34 | 37 | 33 | 46 | 35 |
| EPS (₹) | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 | 5.92 | 8.30 | 6.34 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Rossari Biotech Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 | 2,550 |
| Operating profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 286 | 299 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% | 12% |
| Net profit | 46 | 65 | 80 | 98 | 107 | 131 | 136 | 149 | 151 |
| EPS (₹) | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 26.94 | 27.22 |
TTM is the trailing twelve months to the most recent quarter.
Rossari Biotech Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,322 |
| Borrowings | 8 | 67 | 0 | 8 | 74 | 119 | 218 | 436 |
| Other liabilities | 118 | 118 | 152 | 442 | 375 | 401 | 482 | 505 |
| Total liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,274 |
| Fixed assets | 74 | 94 | 181 | 607 | 585 | 578 | 598 | 784 |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 173 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 62 |
| Other assets | 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,254 |
| Total assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,274 |
As reported by the company. Total assets equal total liabilities by construction.
Rossari Biotech Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 71 | 57 | 48 | 29 | 152 | 43 | 137 | 65 |
| Cash from investing | -37 | -190 | -37 | -299 | -181 | -103 | -183 | -220 |
| Cash from financing | -29 | 157 | -25 | 292 | 61 | 16 | 65 | 186 |
| Net cash flow | 5 | 23 | -14 | 22 | 32 | -44 | 19 | 31 |
| Free cash flow | 27 | -19 | -8 | -7 | 120 | -83 | -21 | -175 |
| CFO / operating profit | 118% | 74% | 64% | 43% | 89% | 39% | 74% | 47% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Rossari Biotech Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 38% | 29% | 24% | 18% | 18% | 16% | 13% |
| Debtor days | 61 | 57 | 74 | 75 | 78 | 85 | 83 | 85 |
| Inventory days | 59 | 57 | 75 | 63 | 59 | 80 | 90 | 88 |
| Days payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 | 71 |
| Cash conversion cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 | 103 |
| Working capital days | 23 | 22 | 60 | 62 | 49 | 70 | 69 | 49 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Rossari Biotech Ltd shareholding pattern
Promoters held 68.14% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.03% and DIIs 14.64%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.27% | 68.19% | 68.18% | 68.18% | 68.18% | 68.15% | 68.15% | 68.14% |
| FIIs | 3.74% | 3.74% | 3.98% | 3.48% | 2.70% | 2.32% | 2.18% | 2.03% |
| DIIs | 17.34% | 17.47% | 17.59% | 17.84% | 18.18% | 18.25% | 18.21% | 14.64% |
| Public | 10.64% | 10.60% | 10.24% | 10.50% | 10.95% | 11.25% | 11.46% | 15.19% |
| No. of shareholders | 97,188 | 95,735 | 92,852 | 91,791 | 91,387 | 89,249 | 86,972 | 87,580 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Rossari Biotech Ltd’s next results date?
Rossari Biotech Ltd’s next results are scheduled for 17 Oct 2026.
- Board meetingApproval of unaudited financial results for quarter and half-year ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Rossari Biotech Ltd corporate filings
- Rossari Biotech schedules Board Meeting on October 17, 2026, to approve unaudited financial results for Q2 FY2027Board Meetinglow impact
Cruxal's analysis: Rossari Biotech Limited has announced a scheduled Board meeting on October 17, 2026, to…
Read the full analysis - Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Rossari Biotech Limited has informed the Exchange regarding the Trading Window Closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.Insider Trading / SASTlow impact
- Rossari Biotech Ltd schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Rossari Biotech has issued an intimation regarding an upcoming analyst and institutional…
Read the full analysis - Rossari Biotech schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Rossari Biotech Ltd has issued an intimation regarding an upcoming analyst and…
Read the full analysis - Rossari Biotech Ltd announces non-participation in scheduled investor and analyst meet on August 10, 2026Company Updatelow impact
Cruxal's analysis: Rossari Biotech has formally intimated that it will not participate in the investors and…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.